共查询到20条相似文献,搜索用时 31 毫秒
1.
2.
Cadarette SM Carney G Baek D Gunraj N Paterson JM Dormuth CR 《Osteoporosis international》2012,23(4):1475-1480
Summary
We compared the patterns of osteoporosis medication prescribing between two provinces in Canada with different public drug coverage policies. Oral bisphosphonates were the primary drugs used, yet access to the second-generation oral bisphosphonates (alendronate, risedronate) was limited in one region. Implications of differential access to oral bisphosphonates warrants further study. 相似文献3.
J. W. Hong W. Nam I.-H. Cha S.-W. Chung H. S. Choi K. M. Kim K. J. Kim Y. Rhee S.-K. Lim 《Osteoporosis international》2010,21(5):847-853
Summary
Bisphosphonate-related osteonecrosis of the jaw (BRONJ) is a serious side effect of bisphosphonate therapy. The incidence of BRONJ is known to be low among patients treated with oral bisphosphonates. We investigated the prevalence, demographics, clinical manifestations, and treatment outcome of 24 patients with oral BRONJ in Asian populations. 相似文献4.
Danielle A Eekman Marijn Vis Irene EM Bultink Harm JGM Derikx Ben AC Dijkmans Willem F Lems 《BMC musculoskeletal disorders》2009,10(1):86-5
Background
In case of contraindications or intolerance during treatment with oral bisphosphonates (OB), administration of pamidronate intravenously is a widely used alternative. 相似文献5.
P. N. Sambrook I. D. Cameron J. S. Chen L. M. March J. M. Simpson R. G. Cumming M. J. Seibel 《Osteoporosis international》2011,22(9):2551-2556
Summary
In a study of 2005 institutionalized older people, use of oral bisphosphonates was associated with a 27% reduction in risk of death compared to non-users after adjusting for potential confounders. 相似文献6.
L. A. Beaupre D. W. Morrish D. A. Hanley W. P. Maksymowych N. R. Bell A. G. Juby S. R. Majumdar 《Osteoporosis international》2011,22(3):983-991
Summary
Intravenous bisphosphonates reduce mortality following hip fracture. We determined whether new use of oral bisphosphonates was also associated with reductions in mortality in 209 hip fracture patients. Oral bisphosphonate exposure led to relative reduction of 8% per month of use (p = 0.001) or about a 60% reduction in mortality per year of use. 相似文献7.
8.
M. M. Wilkes R. J. Navickis W. W. Chan E. M. Lewiecki 《Osteoporosis international》2010,21(4):679-688
Summary
In a cross-design synthesis, total fractures were similarly reduced by bisphosphonates among postmenopausal women in randomized trials (23.8%) and highly compliant/persistent patients in observational studies of large databases from routine practice (20.3%). Bisphosphonates also reduced nonvertebral, vertebral and hip fractures in randomized trials and observational studies. In the real-word setting, compliant/persistent patients can gain a benefit from bisphosphonates comparable to that of randomized trial participants. 相似文献9.
Summary
Many osteoporotic women prescribed strontium ranelate have previously received bisphosphonates. Prior bisphosphonate use blunted the spinal bone mineral density (BMD) response for 6 months. Hip BMD was blunted to a degree for 2 years, although there was an overall increase in hip BMD in contrast to the heel where BMD did not increase. 相似文献10.
F.-E. Cotté P. Fardellone F. Mercier A.-F. Gaudin C. Roux 《Osteoporosis international》2010,21(1):145-155
Summary
This primary care database survey evaluated whether osteoporotic women treated with bisphosphonates were more adherent to monthly than to weekly treatment. Both compliance (medication possession ratio [MPR]) and persistence (time to discontinuation) were superior in the monthly ibandronate treatment group. Better control of fracture risk may thus be achieved using monthly treatment regimens. 相似文献11.
P. Hadji D. Felsenberg M. Amling L. C. Hofbauer J. A. Kandenwein A. Kurth 《Osteoporosis international》2014,25(1):339-347
Summary
Adherence and persistence to oral bisphosphonates in women with postmenopausal osteoporosis is suboptimal. In this study, patients were treated with either oral or intravenous bisphosphonates. The increased adherence and persistence observed in patients receiving intravenous medication compared with those receiving oral medication may improve health outcomes.Introduction
Poor adherence and persistence to oral medication are often observed in women with postmenopausal osteoporosis (PMO). The purpose of the non-interventional BonViva Intravenous Versus Alendronate (VIVA) study was to determine whether, in a real-world setting, (1) increased adherence and persistence to medication would be observed in women with PMO receiving intravenous (i.v.) ibandronate versus oral alendronate, (2) a correlation exists between adherence and persistence to medication and drug efficacy, and (3) any unexpected adverse events/serious adverse events (AEs/SAEs) may occur.Methods
The study was conducted in 632 centers in Germany. A total of 6,064 females with PMO were enrolled and recruited into one of two treatment arms: quarterly i.v. administration of 3 mg ibandronate or weekly oral medication of 70 mg alendronate, for 12 months. At the end of the study, adherence and persistence to medication, new osteoporotic fractures, mobility, use of analgesics, and AEs/SAEs were determined.Results
Greater adherence and persistence to medication were observed in the ibandronate treatment arm compared with the alendronate treatment arm. Although there was no significant difference in the number of patients with new vertebral, hip, or forearm fractures between treatment arms, a significantly greater increase in mobility and decrease in the use of analgesics were reported in the ibandronate treatment arm. No unexpected AEs/SAEs occurred in either arm.Conclusions
Adherence and persistence to medication were greater in women with PMO receiving i.v. ibandronate compared with those receiving oral alendronate. This may have led to an increase in mobility and a decrease in pain in these patients. 相似文献12.
13.
J. Devine S. Trice Z. Finney S. Yarger E. Nwokeji A. Linton W. Davies 《Osteoporosis international》2012,23(4):1415-1424
Summary
This study evaluated whether patients treated with bisphosphonates in the US Military Health System were more compliant with treatment given monthly versus weekly. While medication compliance did improve with treatment given monthly, overall compliance with bisphosphonates was still suboptimal suggesting the need for further strategies to improve compliance with treatment for osteoporosis. 相似文献14.
Use of bisphosphonates and raloxifene and risk of deep venous thromboembolism and pulmonary embolism
P. Vestergaard K. Schwartz E. M. Pinholt L. Rejnmark L. Mosekilde 《Osteoporosis international》2010,21(9):1591-1597
Summary
Prior studies have associated raloxifene and strontium ranelate with deep venous thromboembolism and pulmonary embolism. In a cohort study, we observed an increased risk also with the bisphosphonates. However, the increase was present already before the start of bisphosphonates pointing at an effect of the underlying condition. 相似文献15.
Background
Bisphosphonate-associated osteonecrosis of the jaws (BP-ONJ) is an adverse effect of bisphosphonate treatment with varying reported incidence rates.Methods
In two neighboring German cities, prevalence and additional factors of the development of BP-ONJ in multiple myeloma patients with bisphosphonates therapy were recorded using a retrospective (RS) and cross-sectional study (CSS) design. For the RS, all patients treated from Jan. 2000 - Feb. 2006 were contacted by letter. In the CSS, all patients treated from Oct. 2006 - Mar. 2008 had a physical and dental examination. Additionally, a literature review was conducted to evaluate all articles reporting on BP-ONJ prevalence. PubMed search terms were: bisphosphonat, diphosphonate, osteonecrosis, prevalence and incidence.Results
In the RS, data from 81 of 161 patients could be obtained; four patients (4.9%) developed BP-ONJ. In the CSS, 16 of 78 patients (20.5%) developed BP-ONJ. All patients with BP-ONJ had received zoledronate; 12 of these had had additional bisphosphonates. All except one had an additional trigger factor (tooth extraction [n = 14], dental surgical procedure [n = 2], sharp mylohyoid ridge [n = 3]).Conclusion
The prevalence of BP-ONJ may have been underestimated to date. The oral examination of all patients in this CSS might explain the higher prevalence, since even early asymptomatic stages of BP-ONJ and previously unnoticed symptomatic BP-ONJ were recorded. Since nearly all patients with BP-ONJ had an additional trigger factor, oral hygiene and dental care might help to reduce BP-ONJ incidence. 相似文献16.
J. Sirola K. Salovaara T. Rikkonen M. K?rkk?inen M. Tuppurainen J. S. Jurvelin R. Honkanen H. Kr?ger 《Osteoporosis international》2011,22(1):255-264
Summary
The present study investigated the bone health related factors that were associated with the use of bisphosphonates (BP) among 2,050 postmenopausal Finnish women. Low BMD + low trauma energy fracture was the strongest determinant of BP use, while other secondary causes of osteoporosis were less strongly related with BP use. BP use was associated with reduced femoral neck (FN) and lumbar spine (LS) bone loss rate. 相似文献17.
Jonathan Adachi Niall Lynch Hans Middelhoven Manjit Hunjan Warren Cowell 《BMC musculoskeletal disorders》2007,8(1):97
Background
Sub optimal levels of compliance and persistence with bisphosphonates are potentially compromising the reduction of post menopausal osteoporotic (PMO) fracture risk. 相似文献18.
A. L. Lamberg E. Horvath-Puho S. Christensen H. T. Sørensen 《Osteoporosis international》2010,21(11):1911-1917
Summary
Oral bisphosphonates are widely used for fracture prevention, but there is a concern regarding potential adverse cardiovascular effects of bisphosphonates. In this large, population-based case-control study, we found no evidence of an association between bisphosphonate use and risk of venous thromboembolism (VTE). 相似文献19.
Andrew Deane Leonor Constancio Ignac Fogelman Geeta Hampson 《BMC musculoskeletal disorders》2007,8(1):3
Background
It is still unclear whether addition of calcium/vitamin D supplements leads to an incremental benefit in patients taking bisphosphonates and whether achievement of serum level of 25 (OH) vitamin D of at least 70 nmol/L has an impact on the skeletal response to bisphosphonates. Moreover the maintenance of BMD after bisphosphonates withdrawal with the continuation of calcium/vitamin D supplements only, remains uncertain. The aims were to assess the impact of vitamin D status on changes in bone mineral density (BMD) in firstly patients with post-menopausal osteoporosis on bisphosphonates and secondly following discontinuation of bisphosphonates after long-term use. 相似文献20.